{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:46:52Z","timestamp":1784803612267,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03437-4","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:48:16Z","timestamp":1737694096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exploring practical experience with different treatments in NSCLC patients with MET-deregulated: a retrospective analysis from the real world"],"prefix":"10.1186","volume":"25","author":[{"given":"Mengmeng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"3437_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","volume":"4","author":"M Yuan","year":"2019","unstructured":"Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3437_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","volume":"12","author":"A Drilon","year":"2017","unstructured":"Drilon A, Cappuzzo F, Ou SI, Camidge DR. Targeting MET in Lung Cancer: Will Expectations Finally Be MET? Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer. 2017;12(1):15\u201326.","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"issue":"3","key":"3437_CR3","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.21037\/tlcr-20-1113","volume":"10","author":"M Santarpia","year":"2021","unstructured":"Santarpia M, Massafra M, Gebbia V, D\u2019Aquino A, Garipoli C, Altavilla G, Rosell R. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. Translational lung cancer research. 2021;10(3):1536\u201356.","journal-title":"Translational lung cancer research"},{"issue":"8","key":"3437_CR4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","volume":"5","author":"GM Frampton","year":"2015","unstructured":"Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5(8):850\u20139.","journal-title":"Cancer Discov"},{"issue":"9","key":"3437_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337.","journal-title":"Br J Cancer"},{"issue":"11","key":"3437_CR6","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","volume":"8","author":"YL Wu","year":"2020","unstructured":"Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial. Lancet Respir Med. 2020;8(11):1132\u201343.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3437_CR7","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1016\/j.cllc.2021.11.001","volume":"23","author":"MN White","year":"2022","unstructured":"White MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, Neal JW, Das M, Padda SK, Ramchandran K, Chen TT, Sequist LV, et al. Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. Clin Lung Cancer. 2022;23(3):e210\u201321.","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"3437_CR8","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","volume":"28","author":"K Haratani","year":"2017","unstructured":"Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Annals of oncology\u202f: official journal of the European Society for Medical Oncology. 2017;28(7):1532\u20139.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"key":"3437_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2018.06.001","volume":"122","author":"Y Li","year":"2018","unstructured":"Li Y, Gao L, Ma D, Qiu T, Li W, Li W, Guo L, Xing P, Liu B, Deng L, et al. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. Lung cancer (Amsterdam, Netherlands). 2018;122:113\u20139.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"12","key":"3437_CR10","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","volume":"22","author":"JH Tong","year":"2016","unstructured":"Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, Tong CY, Chow C, Tin EK, Yu YH, et al. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clinical cancer research\u202f: an official journal of the American Association for Cancer Research. 2016;22(12):3048\u201356.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"8","key":"3437_CR11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of oncology\u202f: official journal of the European Society for Medical Oncology. 2019;30(8):1321\u20138.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"4","key":"3437_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","volume":"15","author":"F Guisier","year":"2020","unstructured":"Guisier F, Dubos-Arvis C, Vi\u00f1as F, Doubre H, Ricordel C, Ropert S, Janicot H, Bernardi M, Fournel P, Lamy R, et al. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01\u20132018. Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer. 2020;15(4):628\u201336.","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"issue":"8","key":"3437_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","volume":"5","author":"PK Paik","year":"2015","unstructured":"Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5(8):842\u20139.","journal-title":"Cancer Discov"},{"issue":"10","key":"3437_CR14","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMoa2004407","volume":"383","author":"PK Paik","year":"2020","unstructured":"Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020;383(10):931\u201343.","journal-title":"N Engl J Med"},{"key":"3437_CR15","doi-asserted-by":"crossref","unstructured":"Le XN, Paz-Ares LG, Van Meerbeeck J, Viteri S, Galvez CC, Baz DV, Kim YC, Kang JH, Schumacher KM, Karachaliou N, et al. Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp). J Clin Oncol. 2021;39(15_suppl):9021.","DOI":"10.1200\/JCO.2021.39.15_suppl.9021"},{"issue":"10","key":"3437_CR16","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","volume":"9","author":"S Lu","year":"2021","unstructured":"Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q, Liang Z, Cheng Y, Jiang L, Yang N, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. Lancet Respir Med. 2021;9(10):1154\u201364.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"3437_CR17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(10):944\u201357.","journal-title":"N Engl J Med"},{"key":"3437_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2019.05.011","volume":"133","author":"MM Awad","year":"2019","unstructured":"Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, et al. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung cancer (Amsterdam, Netherlands). 2019;133:96\u2013102.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"9","key":"3437_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100381","volume":"3","author":"SY Kim","year":"2022","unstructured":"Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, Ma PC, Nagasaka M, et al. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO clinical and research reports. 2022;3(9): 100381.","journal-title":"JTO clinical and research reports"},{"key":"3437_CR20","doi-asserted-by":"crossref","unstructured":"Spigel DR, Schrock AB, Fabrizio D, Frampton GM, Sun J, He J, Gowen K, Johnson ML, Bauer TM, Kalemkerian GP, et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1\/PD-L1 targeted therapies. J Clin Oncol. 2016;34(15_suppl):9017.","DOI":"10.1200\/JCO.2016.34.15_suppl.9017"},{"key":"3437_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.649766","volume":"11","author":"L Liu","year":"2021","unstructured":"Liu L, Kalyani FS, Yang H, Zhou C, Xiong Y, Zhu S, Yang N, Qu J. Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study. Front Oncol. 2021;11: 649766.","journal-title":"Front Oncol"},{"key":"3437_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.lungcan.2016.12.001","volume":"103","author":"CH Gow","year":"2017","unstructured":"Gow CH, Hsieh MS, Wu SG, Shih JY. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. Lung cancer (Amsterdam, Netherlands). 2017;103:82\u20139.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"3","key":"3437_CR23","first-page":"1399","volume":"34","author":"JY Hur","year":"2020","unstructured":"Hur JY, Ku BM, Shim JH, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping. In vivo (Athens, Greece). 2020;34(3):1399\u2013406.","journal-title":"In vivo (Athens, Greece)"},{"key":"3437_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2020.08.009","volume":"148","author":"H Yang","year":"2020","unstructured":"Yang H, Zhou Z, Lin L, Yang M, Li C, Li Z, Yu X, Lizaso A, Han-Zhang H, Li B, et al. Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers. Lung cancer (Amsterdam, Netherlands). 2020;148:113\u201321.","journal-title":"Lung cancer (Amsterdam, Netherlands)"},{"issue":"18","key":"3437_CR25","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1158\/1078-0432.CCR-18-0267","volume":"24","author":"M Saigi","year":"2018","unstructured":"Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, Baixeras N, Esteve-Codina A, Nadal E, Brambilla E, et al. MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer. Clinical cancer research\u202f: an official journal of the American Association for Cancer Research. 2018;24(18):4579\u201387.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"11","key":"3437_CR26","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1111\/1759-7714.14448","volume":"13","author":"Y Uehara","year":"2022","unstructured":"Uehara Y, Watanabe K, Hakozaki T, Yomota M, Hosomi Y. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations. Thoracic cancer. 2022;13(11):1703\u201311.","journal-title":"Thoracic cancer"},{"key":"3437_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.863560","volume":"12","author":"J Li","year":"2022","unstructured":"Li J, Feng Y, Tan Y, Duan Q, Zhang Q. Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib. Front Oncol. 2022;12: 863560.","journal-title":"Front Oncol"},{"key":"3437_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.954886","volume":"12","author":"M Fu","year":"2022","unstructured":"Fu M, Feng CM, Xia DQ, Ji ZM, Xia HL, Hu NN, Leng ZJ, Xie W, Fang Y, Cao LJ, et al. Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report. Front Oncol. 2022;12: 954886.","journal-title":"Front Oncol"},{"key":"3437_CR29","doi-asserted-by":"publisher","first-page":"175883592211124","DOI":"10.1177\/17588359221112474","volume":"14","author":"X Ai","year":"2022","unstructured":"Ai X, Yu Y, Zhao J, Sheng W, Bai J, Fan Z, Liu X, Ji W, Chen R, Lu S. Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting. Therapeutic advances in medical oncology. 2022;14:17588359221112474.","journal-title":"Therapeutic advances in medical oncology"},{"issue":"1","key":"3437_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","volume":"26","author":"A Drilon","year":"2020","unstructured":"Drilon A, Clark JW, Weiss J, Ou SI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47\u201351.","journal-title":"Nat Med"},{"issue":"4","key":"3437_CR31","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jtho.2020.11.017","volume":"16","author":"A Kron","year":"2021","unstructured":"Kron A, Scheffler M, Heydt C, Ruge L, Schaepers C, Eisert AK, Merkelbach-Bruse S, Riedel R, Nogova L, Fischer RN, et al. Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of Immunotherapy. Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer. 2021;16(4):572\u201382.","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"issue":"6","key":"3437_CR32","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge DR, Otterson GA, Clark JW, Ignatius Ou SH, Weiss J, Ades S, Shapiro GI, Socinski MA, Murphy DA, Conte U, et al. Crizotinib in Patients With MET-Amplified NSCLC. Journal of thoracic oncology\u202f: official publication of the International Association for the Study of Lung Cancer. 2021;16(6):1017\u201329.","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"key":"3437_CR33","doi-asserted-by":"crossref","unstructured":"Camidge DR, Ou SHI, Shapiro G, Otterson GA, Villaruz LC, Villalona-Calero MA, Iafrate AJ, Varella-Garcia M, Dacic S, Cardarella S, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15_suppl):8001.","DOI":"10.1200\/jco.2014.32.15_suppl.8001"},{"issue":"12","key":"3437_CR34","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","volume":"30","author":"D Moro-Sibilot","year":"2019","unstructured":"Moro-Sibilot D, Cozic N, P\u00e9rol M, Mazi\u00e8res J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, Guibert SD, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial. Annals of oncology\u202f: official journal of the European Society for Medical Oncology. 2019;30(12):1985\u201391.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"1","key":"3437_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","volume":"13","author":"RJ Hartmaier","year":"2023","unstructured":"Hartmaier RJ, Markovets AA, Ahn MJ, Sequist LV, Han JY, Cho BC, Yu HA, Kim SW, Yang JC, Lee JS, et al. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer Discov. 2023;13(1):98\u2013113.","journal-title":"Cancer Discov"},{"issue":"SUPPL 4","key":"3437_CR36","first-page":"150","volume":"43","author":"J Wolf","year":"2020","unstructured":"Wolf J, Overbeck T, Han JY, Hochmair M, De Marinis F, Ohashi K, Smit EF, Power D, Garon EB, Groen HJM, et al. Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Oncology Research and Treatment. 2020;43(SUPPL 4):150\u20131.","journal-title":"Oncology Research and Treatment"},{"issue":"10","key":"3437_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100407","volume":"3","author":"S Lu","year":"2022","unstructured":"Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q, Liang Z, Cheng Y, Jiang L, Yang N, et al. Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations. JTO clinical and research reports. 2022;3(10): 100407.","journal-title":"JTO clinical and research reports"},{"issue":"13","key":"3437_CR38","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/1759-7714.14848","volume":"14","author":"K Miao","year":"2023","unstructured":"Miao K, Zhang X, Wang H, Si X, Zhang L. Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer. Thoracic cancer. 2023;14(13):1162\u201370.","journal-title":"Thoracic cancer"},{"key":"3437_CR39","first-page":"160","volume":"20","author":"K Yoshimura","year":"2017","unstructured":"Yoshimura K, Inui N, Karayama M, Inoue Y, Enomoto N, Fujisawa T, Nakamura Y, Takeuchi K, Sugimura H, Suda T. Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy. Respir Med Case Rep. 2017;20:160\u20133.","journal-title":"Respir Med Case Rep"},{"issue":"62","key":"3437_CR40","doi-asserted-by":"publisher","first-page":"105103","DOI":"10.18632\/oncotarget.21707","volume":"8","author":"S Baldacci","year":"2017","unstructured":"Baldacci S, Mazieres J, Tomasini P, Girard N, Guisier F, Audigier-Valette C, Monnet I, Wislez M, P\u00e9rol M, D\u00f4 P, et al. Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. Oncotarget. 2017;8(62):105103\u201314.","journal-title":"Oncotarget"},{"key":"3437_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722039","volume":"11","author":"L Liu","year":"2021","unstructured":"Liu L, Qu J, Heng J, Zhou C, Xiong Y, Yang H, Jiang W, Zeng L, Zhu S, Zhang Y, et al. A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance. Front Oncol. 2021;11: 722039.","journal-title":"Front Oncol"},{"issue":"6","key":"3437_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nm0607-675","volume":"13","author":"CL Arteaga","year":"2007","unstructured":"Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med. 2007;13(6):675\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"3437_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","volume":"12","author":"Q Wang","year":"2019","unstructured":"Wang Q, Yang S, Wang K, Sun SY. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019;12(1):63.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"3437_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","volume":"31","author":"GR Oxnard","year":"2020","unstructured":"Oxnard GR, Yang JC, Yu H, Kim SW, Saka H, Horn L, Goto K, Ohe Y, Mann H, Thress KS, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Annals of oncology\u202f: official journal of the European Society for Medical Oncology. 2020;31(4):507\u201316.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"issue":"3","key":"3437_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","volume":"21","author":"LV Sequist","year":"2020","unstructured":"Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373\u201386.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3437_CR46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s11523-021-00806-5","volume":"16","author":"K Yoh","year":"2021","unstructured":"Yoh K, Hirashima T, Saka H, Kurata T, Ohe Y, Hida T, Mellemgaard A, Verheijen RB, Ou X, Ahmed GF, et al. Savolitinib \u00b1 Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Target Oncol. 2021;16(3):339\u201355.","journal-title":"Target Oncol"},{"issue":"9","key":"3437_CR47","doi-asserted-by":"publisher","first-page":"S469","DOI":"10.1016\/j.jtho.2022.07.823","volume":"17","author":"MJ Ahn","year":"2022","unstructured":"Ahn MJ, De Marinis F, Bonanno L, Cho BC, Kim TM, Cheng S, Novello S, Proto C, Kim SW, Lee JS, et al. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib plus osimertinib in EGFRm NSCLC Post-Osimertinib. J Thorac Oncol. 2022;17(9):S469\u201370.","journal-title":"J Thorac Oncol"},{"key":"3437_CR48","doi-asserted-by":"publisher","first-page":"S1553","DOI":"10.1016\/j.annonc.2022.10.334","volume":"33","author":"Y Yu","year":"2022","unstructured":"Yu Y, Yang N, Zhang Y, Zhang H, Li M, Yu Q, Zhou J, Hu X, Fang J, Zhao H, et al. SCC244 plus osimertinib in patients with stage IIIB\/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification. Ann Oncol. 2022;33:S1553\u2013S1553.","journal-title":"Ann Oncol"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03437-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:53:14Z","timestamp":1737697994000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03437-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3437"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03437-4","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}